Veoneer downgraded to Sell at UBS on valuation, risk-reward
UBS analyst David Lesne downgraded Veoneer to Sell from Neutral with a $44 price target, citing high valuation and "unattractive" risk-reward. In a research note to investors, Lesne says with shares up since the spinoff, he believes it is already pricing in a potential raise of the 2020 targets and "overly optimistic" sales and profitability outlooks in the long run. He thinks this is "unjustified" due to lack of evidence that organic sales growth is at a turning point in the near-term, adding that Veoneer is "unlikely" to become a leader in Autonomous Vehicles given competition from tech players and risk of OEM software insourcing and hardware commoditization. In the medium-term, Lesne does not see higher sales translating into improved profitability.